Image – Interventional flashlight

DOI: 10.4244/EIJ-D-19-00138

Early experience with a purpose-designed temporary pacing guidewire for transcatheter valve implantation

Mark Hensey1, MB, BCh, BAO; David Daniels2, MD; David Wood1, MD; John G. Webb1, MD

Figure 1. The Wattson temporary pacing guidewire. A) SAPIEN 3 deployment in the aortic position with the Wattson wire. B) Tricuspid valve-in-valve with SAPIEN 3 with the Wattson wire. C) Pigtail with exposed electrodes (arrows). D) Pacing set-up with adaptor connected to external pacing device. E) Connection of adaptor. F) Adaptor release button (arrow).

Transcatheter heart valve implantation generally requires both a ventricular guidewire and a temporary transvenous pacemaker (TVP). TVP insertion is not without risks, namely vascular injury, cardiac perforation and tamponade1. The modification of a ventricular guidewire to deliver unipolar pacing for transcatheter aortic valve implantation (TAVI) has been validated2,3 and has also been described for tricuspid valve-in-valve (TViV) procedures4; however, this requires expertise, adds complexity and may result in high thresholds and unreliable pacing.

We describe the first-in-human experience with the purpose-designed Wattson™ temporary pacing guidewire (Teleflex, Maple Grove, MN, USA) for concomitant valve delivery and pacing. Three patients underwent TAVI and two underwent TViV with a balloon-expandable SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) device (Figure 1A, Figure 1B). All valves were successfully implanted under rapid pacing using the Wattson wire. Mean pacing threshold was 2.2±0.45 mA, with sustained blood pressure drop and no loss of capture in any case. There was no pacing requirement post valve delivery and there were no complications.

Using a guidewire as a concomitant pacing wire reduces the risk of venous access-site complications, fluoroscopic time/dose and, notably, the risk of cardiac perforation. Pacing for TViV is particularly challenging as it may necessitate pacing wire placement in the left ventricle or coronary sinus, or guidewire modification.

The Wattson wire is 0.035” in diameter, 280 cm in length and offers similar stiffness to other commercially available moderate-support guidewires. It has a 3 cm diameter distal pigtail with multiple exposed electrodes providing predictable bipolar pacing (Figure 1C). The wire has an adaptor that connects the wire to a standard external pacemaker (Figure 1D-Figure 1F). If pacing is required post valve deployment, the wire length allows removal of the valve delivery system from the sheath while providing pacing and facilitating TVP insertion. In patients at high risk of needing longer-term pacing (e.g., pre-existing high degree atrioventricular block), an indwelling TVP might still be preferred.

In this small series, the Wattson wire offered reliable pacing and rail support for valve delivery in aortic and tricuspid positions. It could potentially make transcatheter valve implantation safer and more efficient but requires further clinical validation.

Conflict of interest statement

D. Daniels will receive royalties from the Wattson temporary pacing guidewire. D. Wood is a consultant to Edwards Lifesciences. J.G. Webb is a consultant to and has received research funding from Edwards Lifesciences, Abbott and Boston Scientific. The other author has no conflicts of interest to declare.

Volume 15 Number 6
Aug 9, 2019
Volume 15 Number 6
View full issue


Key metrics

On the same subject

Research correspondence

10.4244/EIJ-D-23-00369 Nov 17, 2023
Direct wire pacing for transcatheter mitral valve replacement
Servoz C et al

Clinical research

10.4244/EIJ-D-18-01060 Nov 15, 2019
Pacemaker dependency after transcatheter aortic valve implantation: incidence, predictors and long-term outcomes
Costa G et al
free

EXPERT REVIEW

10.4244/EIJ-D-17_00487 Sep 24, 2017
Transcatheter tricuspid valve intervention: state of the art
Taramasso M and Maisano F
free

10.4244/EIJV13I11A196 Dec 20, 2017
A new hope - low permanent pacemaker rates with self-expanding transcatheter heart valves
Hengstenberg C and Husser O
free
Trending articles
338.03

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
284.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
226.03

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
209.5

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
168.4

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
150.28

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
118

Translational research

10.4244/EIJ-D-22-00718 Jun 5, 2023
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds
Seguchi M et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved